ImetelChat

As is common knowledge, Janssen and Geron have a second license agreement signed following the imetelstat collaboration agreement. Janssen licensed additional patents and rights from Geron to develop new drugs outside the field of telomerase inhibition. The agreement provides for annual license fees, as well as confidential milestone payments for various drug development milestones and royalties on commercial sales. Janssen is required to provide Geron with an annual report of research activities on the anniversary of the agreement, which was September 15. So, in addition to working on the continuation decision from the imetelstat agreement, Janssen also needed to report on its activities under the second license agreement as well. https://www.sec.gov/Archives/edgar/data/886744/000110465916154548/a16-17207_1ex10d1.htm

J6, thank you for calling this to the boards attention. I was always perplexed as to when Scarlett jettisoned the stem cell side that he also "appeared" to jettison Sergei, one who should be protected and revered, but clearly as we looked to see where he landed years ago it was a safe place within Janssen, presumably to continue his seminal work. This second agreement is worthy of close follow up. bp

Thanks so much. Had no idea this existed. Great research. Curious as to what made you even think to search for it. Regardless, nice find. Hope you don't mind if I pass this on to the fevered masses. Shall add fuel to the endless, ( and sometimes mindless) speculation...which, if nothing else is entertaining. Again, thank you!!